Goldman Sachs, BofA Securities and Evercore ISI are the joint bookrunners on the deal. It plans to list on the Nasdaq under the symbol FDMT.
EMERYVILLE CA 4D MOLECULAR THERAPEUTICS LICENSE
It has two additional candidates that it expects to file INDs for in the 2H21.ĤD Molecular Therapeutics was founded in 2013 and booked $17 million in collaboration and license revenue for the 12 months ended September 30, 2020.
EMERYVILLE CA 4D MOLECULAR THERAPEUTICS TRIAL
Its lead candidates include 4D-125, which is currently in a Phase 1/2 trial for X-linked retinitis pigmentosa with initial data expected in 2021 4D-110, which is currently in a Phase 1 trial for choroideremia with initial data expected in 2022 and 4D-310, which is currently in a Phase 1/2 trial for Fabry disease with initial data expected in 2021. At the midpoint of the proposed range, 4D Molecular Therapeutics would command a fully diluted market value of $491 million.ĤD is developing product candidates using its targeted and evolved AAV vectors, initially focusing on ophthalmology, cardiology, and pulmonology. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)Ĭalendars and Economy: 'Actual' numbers are added to the table after economic reports are released.4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.Ĭryptocurrencies: Cryptocurrency quotes are updated in real-time. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright © Refinitiv. Data may be intentionally delayed pursuant to supplier requirements. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Source: FactSetĭata are provided 'as is' for informational purposes only and are not intended for trading purposes. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Sources: FactSet, Tullett PrebonĬommodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Sources: FactSet, Tullett PrebonĬurrencies: Currency quotes are updated in real-time. Sources: FactSet, Dow Jonesīonds: Bond quotes are updated in real-time. Sources: FactSet, Dow JonesĮTF Movers: Includes ETFs & ETNs with volume of at least 50,000. Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Overview page represent trading in all U.S. Indexes: Index quotes may be real-time or delayed as per exchange requirements refer to time stamps for information on any delays. Emeryville, California Type Public Company Founded 2013 Specialties Gene Therapy, Adeno-Associated Virus, Biotechnology, Rare Diseases, Clinical, Lab, Clinical Trials, and Science Locations. Copyright © FactSet Research Systems Inc. Fundamental company data and analyst estimates provided by FactSet. International stock quotes are delayed as per exchange requirements. stock quotes reflect trades reported through Nasdaq only comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. at $8.04 per shareĭerivative/Non-derivative trans. at $6.49 per shareĭerivative/Non-derivative trans. Bizily Chief Legal and HR Officerĭerivative/Non-derivative trans.
0 kommentar(er)
